China SXT Pharmaceuticals Issues 66.67 Million Shares at $0.15 Each
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Financing Scale: China SXT Pharmaceuticals has entered into an agreement with a single investor to issue 66.67 million Class A ordinary shares at $0.15 each, expecting to raise approximately $10 million, which will enhance the company's liquidity to support future growth.
- Transaction Timing: The transaction is expected to close around January 12, 2026, subject to customary closing conditions, ensuring timely access to funds to meet operational needs.
- Underwriter Role: Univest Securities, LLC is acting as the sole placement agent for this offering, indicating a professional partnership in the capital markets that helps enhance market confidence.
- Compliance Statement: The offering is made pursuant to an F-3 registration statement that became effective on December 1, 2025, ensuring compliance and providing transparent disclosures to investors, thereby reducing legal risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SXTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SXTC
About SXTC
China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
China SXT Pharmaceuticals Announces Share Consolidation
- Share Consolidation Ratio: China SXT Pharmaceuticals announced a 1-for-150 share consolidation effective February 3, 2026, which will reduce the outstanding shares to approximately 957,960, significantly impacting shareholder equity and market liquidity.
- Exchange Continuity: Post-consolidation, the ordinary shares will continue trading on Nasdaq under the symbol "SXTC" with a new CUSIP number G2161P165, ensuring seamless trading for investors after the consolidation.
- Shareholder Rights Adjustment: All outstanding stock options, warrants, and other rights to purchase shares will be proportionately adjusted to reflect the consolidation, safeguarding shareholder interests and maintaining governance transparency.
- Investor Communication: The company advises shareholders to contact their banks, brokers, or nominees for details regarding the consolidation, ensuring timely and accurate information dissemination to bolster investor confidence and reduce market uncertainty.
Continue Reading
China SXT Pharmaceuticals Announces 1-for-150 Share Consolidation
- Capital Structure Adjustment: China SXT Pharmaceuticals announced a 1-for-150 share consolidation effective February 3, 2026, reducing its Class A shares from approximately 143.7 million to about 957,960, which aims to optimize its capital structure and enhance per-share value.
- Exchange Change: Post-consolidation, the Class A shares will trade on Nasdaq under the new symbol “SXTC,” with a new CUSIP number coming into effect, which is expected to improve market visibility and liquidity.
- Rights Adjustment: All outstanding options, warrants, and other rights to purchase Class A shares will be adjusted proportionately, ensuring that shareholder rights are preserved, thereby maintaining investor confidence.
- Market Reaction: Following the announcement of the consolidation, SXTC's stock price fell by 21.4% to $0.0393, reflecting a cautious market sentiment regarding the decision, which may impact the company's future financing capabilities and investor sentiment.
Continue Reading